The BFA released from nanoparticles could promote ER stress‐associated ICD and CD8+ T‐cell recruitment, and combined with JQ1 overcame ICD‐induced PD‐L1 enrichment; thus, synergistically improving the anti‐melanoma therapy efficiency and boosting long‐term antitumor immunity in a CD8+ T‐cell‐dependent manner.[117]. The gene discussed is CD8A; the disease is melanoma.